secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008448
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates
--------------------------------------------------------------------------------

- Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.
- Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.
- CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.
- Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/0000950170-23-008448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/sprb-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer